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Abstract
Background
The sites of mycobacterial infection in the lungs of tuberculosis (TB) patients have complex
structures and poor vascularization, which obstructs drug distribution to these hard-to-reach
and hard-to-treat disease sites, further leading to suboptimal drug concentrations, resulting
in compromised TB treatment response and resistance development. Quantifying lesion-
specific drug uptake and pharmacokinetics (PKs) in TB patients is necessary to optimize
treatment regimens at all infection sites, to identify patients at risk, to improve existing regi-
mens, and to advance development of novel regimens. Using drug-level data in plasma and
from 9 distinct pulmonary lesion types (vascular, avascular, and mixed) obtained from 15
hard-to-treat TB patients who failed TB treatments and therefore underwent lung resection
surgery, we quantified the distribution and the penetration of 7 major TB drugs at these
sites, and we provide novel tools for treatment optimization.
Methods and findings
A total of 329 plasma- and 1,362 tissue-specific drug concentrations from 9 distinct lung
lesion types were obtained according to optimal PK sampling schema from 15 patients
(10 men, 5 women, aged 23 to 58) undergoing lung resection surgery (clinical study
NCT00816426 performed in South Korea between 9 June 2010 and 24 June 2014). Seven
major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifloxacin [MFX], clofazi-
mine [CFZ], pyrazinamide [PZA], and kanamycin [KAN]) were quantified. We developed
and evaluated a site-of-action mechanistic PK model using nonlinear mixed effects method-
ology. We quantified population- and patient-specific lesion/plasma ratios (RPLs),
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002773 April 2, 2019 1 / 26
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Strydom N, Gupta SV, Fox WS, Via LE,
Bang H, Lee M, et al. (2019) Tuberculosis drugs’
distribution and emergence of resistance in
patient’s lung lesions: A mechanistic model and
tool for regimen and dose optimization. PLoS Med
16(4): e1002773. https://doi.org/10.1371/journal.
pmed.1002773
Academic Editor: Megan Murray, Harvard School
of Public Health, UNITED STATES
Received: August 10, 2018
Accepted: February 28, 2019
Published: April 2, 2019
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was carried out with funding
from US National Institutes of Health (NIH) grants
R01AI106398-01 and R01AI111967 (RS and VD),
grant OPP1066499 (VD) from the Bill and Melinda
Gates Foundation, the Intramural Research
Program of the NIH National Institute of Allergy
and Infectious Diseases (CEB), the Critical Path to
dynamics, and variability of drug uptake into each lesion for each drug. CFZ and MFX had
higher drug exposures in lesions compared to plasma (median RPL 2.37, range across
lesions 1.26–22.03); RIF, PZA, and LZD showed moderate yet suboptimal lesion penetra-
tion (median RPL 0.61, range 0.21–2.4), while INH and KAN showed poor tissue penetration
(median RPL 0.4, range 0.03–0.73). Stochastic PK/pharmacodynamic (PD) simulations
were carried out to evaluate current regimen combinations and dosing guidelines in distinct
patient strata. Patients receiving standard doses of RIF and INH, who are of the lower range
of exposure distribution, spent substantial periods (>12 h/d) below effective concentrations
in hard-to-treat lesions, such as caseous lesions and cavities. Standard doses of INH (300
mg) and KAN (1,000 mg) did not reach therapeutic thresholds in most lesions for a majority
of the population. Drugs and doses that did reach target exposure in most subjects include
400 mg MFX and 100 mg CFZ. Patients with cavitary lesions, irrespective of drug choice,
have an increased likelihood of subtherapeutic concentrations, leading to a higher risk of
resistance acquisition while on treatment. A limitation of this study was the small sample
size of 15 patients, performed in a unique study population of TB patients who failed treat-
ment and underwent lung resection surgery. These results still need further exploration and
validation in larger and more diverse cohorts.
Conclusions
Our results suggest that the ability to reach and maintain therapeutic concentrations is both
lesion and drug specific, indicating that stratifying patients based on disease extent, lesion
types, and individual drug-susceptibility profiles may eventually be useful for guiding the
selection of patient-tailored drug regimens and may lead to improved TB treatment out-
comes. We provide a web-based tool to further explore this model and results at http://
saviclab.org/tb-lesion/.
Author summary
Why was this study done?
• Tuberculosis (TB) remains the number one infectious disease killer, with patients failing
treatment despite use of multidrug curative treatment.
• The potential reason for suboptimal response is reduced drug penetration to the diverse
lung lesions formed by the host immune system, in which the bacteria remains in the
secluded areas inaccessible to the drug.
What did the researchers do and find?
• We developed a mathematical model for 7 major TB drugs by utilizing actual patient
data, which describes the amount and rate of drug penetration into 9 distinct TB lesions
in which mycobacteria reside.
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• The majority of TB drugs show poor penetration into the cavitary lesions, leading to
inadequate drug levels at the site of the disease.
• Multidrug-level simulations to identify favorable drug combinations for cure at the site
of infection showed that a combination of clofazimine (CFZ) and moxifloxacin (MFX)
or CFZ and linezolid (LZD) would be optimal for patients presenting with caseous
lesions.
What do these findings mean?
• Drugs do not penetrate equally in different tissues, and considering that a variety of TB
patients presented with unique lesion subtypes and lung pathology, the current one regi-
men to fit all approaches is inadequate to treat every patient.
• To maximize cure, a patient-focused approach is needed for which clinical phenotype
should be used to match the right drug regimen to the right patient.
Introduction
A primary objective of contemporary tuberculosis (TB) drug development programs is the
identification of therapeutic regimens that have shorter treatment duration and improved effi-
cacy with decreased risk of resistance [1]. Similarly, therapeutic use of the current regimen for
drug-sensitive (DS)-TB can further be optimized, as its current use, despite high efficacy of the
regimens (>95%) in the clinical trials, leads to unsatisfying effectiveness in the field and emer-
gence of resistance [2–4]. Further, both efficacy and effectiveness of regimens for all forms of
drug-resistant TB can further be optimized to reach high cure rates. A significant barrier to
improving TB regimens is the complex pathology of TB in human lung tissue. Drug access to
the site of mycobacterial infection becomes increasingly difficult as the disease progresses
from initial macrophage infection to the formation of heterogeneous granuloma lesions that
have variable or limited blood supply [5,6]. In a clinical research study of drug distribution
into TB lesions [7], imaging and conventional mass spectrometry of resected lung lesions from
patients with multidrug-resistant (MDR)-TB showed that the distribution patterns of TB
drugs within these diverse lesions vary significantly and that, in many cases, drug concentra-
tions in lesions correlate poorly with concentrations measured in blood [7,8]. Presence of cavi-
tary lesions and extensive lung pathology has been established as a major risk factor for poor
TB outcomes, which could be explained by reduced drug penetration at these sites. Recent
translational studies of rifapentine’s poor penetration properties in the cavitary lesions quanti-
tatively predicted and explained substantially longer times of culture conversion observed in
patients with large cavitation and comparably high blood exposures [9,10]. Drug regimens
designed solely based on plasma pharmacokinetic (PK) profiles are therefore inadequate to
predict the true sterilizing effect of drugs at the site of mycobacterial infection, especially for
the drugs that have reduced or variable penetration at the site of infection. Additionally, myco-
bacterial resistance may be driven by this differential drug exposure in infected TB lesions, for
which windows of monotherapy at selected times and locations likely increase drug pressure.
Our goal is to provide a data-driven framework and tool that enables quantification of lesion-
specific information in addition to dosing regimens and microbiological PK/
Tuberculosis drugs’ distribution, PK, and resistance in patient lung lesions
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pharmacodynamic (PD) parameters and can serve the TB community at multiple levels, such
as a) treatment optimization to achieve cure, b) profiling high-risk populations based on
reduced penetration in hard-to-treat lesions with the current regimens, and c) in silico investi-
gation and optimization of novel regimens that achieve sterilization and prevent resistance
development.
Here, (1) to our knowledge, we report for the first time the penetration of kanamycin
(KAN) and linezolid (LZD) in human TB lesions; (2) we report a population lesion-focused
PK model and parameters from the observed concentration–time profiles in TB patients of
first-line drugs isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) and second-line
drugs moxifloxacin (MFX), KAN, clofazimine (CFZ), and LZD in 9 distinct human lesion-spe-
cific tissues: uninvolved lung, closed nodules (cellular, necrotic, or fibrotic), cavity wall, cavity
caseum or nodule caseum, and fungal ball; (3) we profile by means of stochastic population
simulations the clinical utility of these 7 drugs within a regimen with a focus on identifying
underexposed lesions, suboptimal doses and regimens, and patient subgroups at risk of relapse
and resistance development; and (4) we provide a tool that can be used by scientific and clini-
cal communities to evaluate the lesion-focused time course of drug levels following various
drug combinations, doses, and schedules.
Methods
Patient, drug regimen, and surgical procedure details
Original clinical trial design and partial raw data on RIF, INH, PZA, CFZ, and MFX in plasma,
lung tissue, and lesions of TB patients were previously reported in Prideaux and colleagues,
and these data were added to our database; the original prospective protocol is included as S1
Study protocol [7]. Briefly, 15 patients who failed initial TB treatment and who were receiving
selected first- and second-line TB drugs underwent elective lung resection surgery to debulk
tubercular lung disease at the National Masan TB Hospital and Asan and Samsung Medical
Center in Seoul and Pusan National University Hospital in Pusan, Republic of Korea. The
study was approved by the Institutional Review Board of the National Institute of Allergy and
Infectious Diseases and by the institutional review boards of the hospitals conducting the
study in the Republic of Korea. The subjects gave written informed consent to participate in
the study and to have their resected tissue used for research. Exclusion criteria included
patients younger than 20, women pregnant or unwilling to avoid pregnancy, and HIV positive.
S1 Study protocol contains specific details regarding comorbidity and concomitant drug exclu-
sions. All patients received single-dose tablets of 600 mg RIF, 300 mg INH, 1,500 mg PZA, 400
mg MFX, and 1,000 mg KAN dissolved in 5 ml normal saline (0.9% NaCl) before their sched-
uled surgery. Patients taking LZD and CFZ as part of their background regimens were consid-
ered at steady state if they had been on the drugs for more than 14 days. Patients receiving
other drugs that were not the approved study drugs, such as LZD and CFZ, were not given
these drugs on the day of surgery to minimize drug–drug interactions. These background
drugs were still quantified and included in the data set analyzed and modeled in the present
work, including appropriate dosing histories that had the exact times of their previous LZD
and CFZ dose, which occurred more than 24 h before surgery. The lower limits of quantifica-
tion (LOQ) were 1 ng/mL in plasma and 10 ng/g in tissue for both CFZ and LZD. Individual
patient dosing times were planned to occur at approximately 2, 4, 8, 12, or 24 h before surgery
with the aim of collecting longitudinal tissue sample concentrations. Plasma samples were
drawn prior to and at the time of surgery. The PK sampling times served as proposed times,
and no interference to the surgery occurred to obtain exact PK times. The drug administration
was timed to occur before the surgery at various time points so different patients could
Tuberculosis drugs’ distribution, PK, and resistance in patient lung lesions
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contribute lesion samples at different time points post dose to reconstruct the entire PK
profile. The exact resection times were recorded, and collected lung tissues were classified and
dissected into defined lesions by macroscopic appearance and flash frozen for drug quantifica-
tion. During resection, the pulmonary artery was clamped and resected tissue very briefly
rinsed to avoid blood contamination in the tissue. Samples were further classified by histologi-
cal and radiological methods into lung, necrotic nodule, caseum from closed nodule, caseous
fibrotic nodule, caseum from cavity, cavity wall, fibrotic tissue, small nodule, and fungal ball
(S1 Fig), quantified by HPLC-coupled tandem mass spectrometry (LC/MS-MS), and imaged
by matrix-assisted laser desorption-ionization mass spectrometry imaging (MALDI-MSI). For
large enough lesions that had discrete necrotic content, the lesion walls and caseum were ana-
lyzed separately.
Plasma PK models
Plasma compartmental models were built for each drug based on established methodology. To
capture the absorption, distribution, and clearance of the drugs, 1- and 2-compartment models
with first-order elimination, parameterized in terms of oral clearance (CL), oral volume of dis-
tribution (V), peripheral volume of distribution (V2), and intercompartmental clearance
accounting for drug movement between central and peripheral volume of distribution (Q),
were tested and fitted to the data. To describe the process of absorptions, different established
models were explored for the absorption profile of the drugs: a straight forward first-order
model and, if necessary, a lag time and a transit compartment model with a fixed or estimated
number of compartments were evaluated [11,12]. Within a population, we expect variability in
some PK parameters, and to account for this distribution, interindividual variability (IIV)
parameter was tested on plasma PK parameters and allowed based on the magnitude of esti-
mates and the likelihood ratio test (LRT), which acts as a measure of statistical significance.
The plasma PK model for PZA, MXF, KAN, CFZ, and LZD was a 1-compartment model
with first-order absorption described by the following equation:
dA
dt
¼ ka � A1  
CL
V
� �
� A2; ð1Þ
in which A1 is the amount of drug in the absorption compartment, A2 is the amount of drug in
the central compartment in milligrams, CL is the clearance in liters per hour, and V is the vol-
ume of distribution in liters.
RIF PKs were described with a 1-compartment model linked to the transit compartment
absorption chain, as described in Savic and colleagues [12], while the INH model was a 2-com-
partment model with first-order absorption.
Tissue penetration model
Penetration of each drug into lung and lesions was described using a separate lesion compart-
ment, as described by Kjellsson and colleagues [13], according to the following equations:
dClung
dt
¼ kpl  lung � Rlung  pl �
Aplasma
Vplasma
  Clung
 !
; ð2Þ
dClesion
dt
¼ kpl  lesion � Rlesion  pl �
Aplasma
Vplasma
  Clesion
 !
; ð3Þ
in which Clung and Clesion represent the drug concentration within uninvolved lung and lesion,
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KPL−lung and KPL−lesion are intercompartment rate constants for the transfer of drug from the
plasma to lung or lesion, Rlung−pl and Rlesion−pl are the penetration coefficients (ratios) between
lung or lesion and plasma, and Aplasma/Vplasma is the drug concentration in plasma at time t. If
the ratio value is 1, there is equal distribution between plasma and tissue; if the ratio is<1,
there is reduced drug penetration from plasma to the tissue, and if the ratio is >1, there is
accumulation of drug in the tissue compared to the plasma.
Population PK model selection and evaluation
Concentration–time data for each drug in plasma, lesions, and uninvolved lung from each
patient were modeled using a population PK methodology, which is the appropriate method
for sparse longitudinal data with expected variability between patients and separation of the
signal from noise due to random error. To best fit the sparse longitudinal data, we used nonlin-
ear mixed-effects models with first-order conditional estimation methods as implemented in
the software NONMEM (version 7.3; ICON Development Solutions, Ellicott City, MD, United
States). Graphical, statistical, and exploratory analyses were conducted using the open-source
software R (version 3.3.1). The Xpose (version 4.0) package, implemented within R, was used
for graphical evaluations and visual predictive checks [14].
A stepwise approach was taken to model fitting. First, a structural PK model was fit to the
plasma PK data, which contained the longitudinal samples in each patient, required to describe
the population distribution. After establishing and validating the plasma PK model, PK data in
uninvolved-lung and individual-lesion subtypes were added one lesion at a time, and the
model was expanded in a stepwise manner, followed by assessment of parameters and good-
ness of fit. The plasma/lesion ratios and rates of drug uptake into the lesion compartments
were estimated. It was assumed that the drug distribution into the lesion can only happen
from the plasma, given general physiological knowledge of drug distribution. S2 Fig shows the
influence of these KPL and RPL parameters on the PK profile from plasma to lesion, for which
KPL influences the temporal delay as related to the plasma profile and RPL the magnitude
change of the concentration in the tissue compared to plasma concentration. To account for
accumulation of drugs into the lesions for patients at steady state, the lesion compartments
were never reset after the dosing. To account for potential noise in the data, additive and pro-
portional error models of residual variability were explored. Different residual errors were esti-
mated for plasma, lung, and lesions. The LRT was used to evaluate statistical significance for
inclusion of additional parameters in the nested models, with a decrease of 3.84 points (pro-
portional to −2 log likelihood change), considered statistically different with 5% significance
level assuming the LRT is X2 distributed. No additional variability was added to the lesion
parameters, as the data were too sparse with a single-time point per patient. The variance seen
for the lesion PKs follows expected plasma variance.
Finally, individual and population predictions of exposures at steady state were estimated
in terms of the area under the concentration–time curve over 24 h at steady state (AUC0–24)
and peak concentration (Cmax) in plasma, lung, and each lesion subtype. Simulations achieved
2 goals: (1) evaluation of the performance properties of selected models (visual predictive
checks) and (2) exploration of PKPD relationships with alternative dosing scenarios.
PK/PD exposure target selection
Antibiotic exposure to determine effective activity can be quantified using PK/PD indices: area
under the concentration curve (AUC), maximum concentration (Cmax), and time, all relative
to minimum inhibitory concentration (MIC). The final population PK parameters and interin-
dividual variability were used to simulate PK profiles over the course of the treatment.
Tuberculosis drugs’ distribution, PK, and resistance in patient lung lesions
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Distributions of wild-type MIC were obtained from published epidemiological data based on
clinical isolates tested according to standardized EUCAST/CLSI methodology as well as litera-
ture [15,16]. Target attainment analyses were performed using the upper limit of the published
wild-type MIC distributions for each drug. Target analysis was not possible for PZA due to the
drug’s apparent lack of antimycobacterial activity in vitro under standardized pH-acidic con-
ditions. All simulations were performed using the mlxR package in R, with the final estimates
and patient distribution from the established clinical PK model [17,18].
Implementation of the model into interactive tool
A user interface to allow rapid simulations of the described lesion model and predict new data
based on dosing regimen, microbiology values, and patient distribution was developed using
the Shiny package from Rstudio [19,20]. The web application utilized the mlxR package for
calculating and running the population model [17]. The code used is available within the web
application and can be found at http://saviclab.org/tb-lesion/.
Results
Subject demographics and observed PK profiles
Previously described clinical study NCT00816426 collected lung lesion samples after elective
lung resection from 10 male and 5 female patients aged 23 to 58 who failed TB treatment [7].
The demographics of the individual patients and their respective steady-state drugs are pre-
sented in Table 1. The PK data collected included samples from uninvolved lung, necrotic
nodule, caseum from closed nodule, caseous fibrotic nodule, caseum from cavity, cavity wall,
fibrotic tissue, small nodule, and fungal ball over a time range of 3–33 h, and plasma samples
Table 1. Patient demographics.
Subject Gender Age (yrs) BMI (kg/m2) Prior TB episodes Study steady-state drugs Other steady-state drugs NAT2 Polymorph (phenotype§)
1 Male 27 24.0 2 MFX, KAN LZD, AUG, CLA NAT2�4 (Fast)
2 Male 51 22.3 1 - LFX NAT2�4 (Fast)
3 Male 40 17.3 2 INH EMB NAT2�4 (Fast)
4 Female 53 22.0 8 - - ¥NAT2�6A (Intermediate)
5 Male 54 29.4 2 - LZD, AMK, PAS, CFZ NAT2�4 (Fast)
6 Female 48 22.2 1 MFX LZD, CS, AMX, PTH NAT2�4 (Fast)
7 Male 43 27.1 2 MFX, KAN LZD, PAS, AUG NAT2�4 (Fast)
8 Male 59 19.2 1 - - NAT2�6 A (Slow)
9 Male 36 24.8 1 MFX, KAN, PZA LZD, CS, PAS, PTH NAT2�4 (Fast)
10 Female 23 18.8� 2 - LZD, CS, CFZ ¥NAT2�7B (Intermediate)
11 Male 47 18.9 1 INH LZD, CS, AUG, PTH, STM NAT2�4 (Fast)
12 Male 39 22.2 4 PZA CS, LFX, PTH, STM NAT2�4 (Fast)
13 Female 58 21.2 1 KAN LZD, CS, PAS NAT2�4 (Fast)
14 Female 27 20.0 1 PZA LZD, CS, AUG, STM NAT2�4 (Fast)
15 Male 44 24.1 1 INH, PZA EMB, LFX NAT2�6A (Slow)
Abbreviations: AMK, amikacin; AUG, amoxicillin/clavulanate; CFZ, clofazimine; CLA, clarithromycin; CS, cycloserine; EMB, ethambutol; INH, isoniazid; KAN,
kanamycin; LFX, levofloxacin; LZD, linezolid; MFX, moxifloxacin; NAT2, N-acetyltransferase 2; PAS, para-aminosalicylate; PTH, prothionamide; PZA, pyrazinamide;
RIF, rifampicin; STM, streptomycin.
�Patient received LZD 450-mg dose due to low BMI.
§Acetylator phenotype inferred from NAT2 genotype.
¥Heterozygous allele.
https://doi.org/10.1371/journal.pmed.1002773.t001
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were taken prior to and at the time of surgery, with a total of 329 plasma and 1,362 lesion data
points above LOQ included in the analysis. A summary of the number of observations for each
drug, lesion, and number of patients contributing to each compartment can be found in S1
Table. The observed data of measured drugs in their respective lesions are shown in Fig 1.
Drug concentrations differed greatly among lesions and patients and even within similar
lesions of a single patient, demonstrating the high variance of TB drug distribution into lung
lesions. Plasma and lesion concentrations of KAN and LZD are reported here for the first time
(S1 Data) as well as spatial distribution of LZD and CFZ as measured by two-dimensional
MALDI-MSI (Fig 2). From Fig 2, we observe that LZD seems to distribute equally between
caseum and cellular tissue, suggesting high penetration into caseum. In contrast, CFZ shows
little penetration into the caseum region and has a much higher affinity for cellular tissues sur-
rounding the caseum area.
Fig 1. Raw clinical data for each drug in each lesion type. Concentration–time profiles are shown for 9 lesions and 7 drugs by respective panel. Plasma concentrations
over time for each individual were measured at multiple time points after the time of drug administration and before lung resection and are shown as individual lines of
different colors. Lesion concentrations were measured at a single time point (time of resection) per subject and are represented by circles of different colors that
correspond to their individual subject plasma line. Closed circles show patients assumed to be at steady state, and open circles show patients receiving the drug for the
first time. Some subjects received LZD and CFZ in their background regimen, and their last CFZ and LZD doses were administered on the day preceding the resection,
leading to tissue samples after 24 h. None of the patients receiving LZD and CFZ had fungal ball lesions, and those patients on CFZ also didn’t have closed nodule
caseum lesions. CFZ, clofazimine; INH, isoniazid; KAN, kanamycin; LZD, linezolid; MFX, moxifloxacin; NA, not available; PZA, pyrazinamide; RIF, rifampicin.
https://doi.org/10.1371/journal.pmed.1002773.g001
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Plasma and tissue PK model
The structural model describing the plasma PKs and distribution of RIF, INH, PZA, MFX,
KAN, LZD, and CFZ in the 9 lung tissue compartments is summarized in Fig 3. A 1-compart-
ment model with first-order absorption best described the plasma data of PZA, MFX, KAN,
LZD, and CFZ. RIF model–building required a transit absorption compartment to capture the
observed absorption data, and INH PKs best fit a 2-compartment model with first-order
absorption and lag time. INH undergoes N-acetyltransferase 2 (NAT2) mediated conversion
to acetyl-INH in the liver. Due to widespread genetic polymorphisms in NAT2 and a demon-
strated correlation between polymorphism and INH concentration–time profile [21], INH
profiles were characterized for slow, intermediate, and fast acetylators with 11 out of the 15
subjects phenotyped as fast acetylators, i.e., high metabolizers. Further discussion, therefore,
focuses on fast acetylators and their increased risk of treatment failure. Established models
were evaluated by a visual predictive check of the final model, stratified by drug and lesion,
shown in simplified Fig 4 indicating appropriate model fit with overlapping of first dose and
steady state. A more complete plasma concentration visual predictive check is provided in S3
Fig. The final estimates of the parameter values from the plasma PK models are shown in
Fig 2. Two-dimensional imaging of LZD and CFZ by MALDI-MS. MALDI-MS ion maps of LZD and CFZ that provide a semiquantitative measure using the relative
ion abundance of specific analytes in regions of interest. The highest signal intensity is fixed to 100% for each drug (red) and 0% indicating no detectable drug present
(blue) on the rainbow color scale bar to the right. The caseum area is demarcated by the white line in the MALDI-MS image and corresponds to the black line of the
histologically stained lesion images of the same sample in the bottom panel. A. The top panel of a nodule caseum and cavity lesion resected 20 h after LZD
administration. LZD partitions favorably into cavity and nodule caseum in vivo, as indicated by the green color present in caseum and surrounding tissue showing
similar concentrations in both. B. Clofazimine at steady state and 5 h post dose shows low penetration into the large necrotic granuloma in the top panel, as indicated
by the blue area. CFZ, clofazimine; LZD, linezolid; MALDI-MS, matrix-assisted laser desorption-ionization mass spectrometry.
https://doi.org/10.1371/journal.pmed.1002773.g002
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Table 2. Clearance values for all drugs except INH were within reported literature ranges, as
shown in the S2 Table, showing that this subpopulation of patients exhibits similar PK profiles
to the general population. Tissue distribution was best described by separate compartment
with 2 distinct parameters: parameter to describe the rate of drug movement from plasma to
each lesion type or compartment (KPL) and a parameter to estimate the ratio of drug concen-
tration observed in the tissue compared to the concentration in plasma (RPL). Table 3 shows
the final estimated penetration ratios of each drug in the 9 types of lung and lesion compart-
ments. The plasma-to-tissue distribution rate constants are detailed in S3 Table.
Fig 3. PK structural model. First-line drugs R, H, and PZA and second-line drugs M, C, K, and L were modeled
individually with parameters CL, V, and ka from an A describing Cps. R required a transit model to capture
absorption, and H required an additional compartment (P) with Q and lag in time before absorption (Tlag) to model
plasma data. Tissue concentration–time profiles were modeled with the addition of 2 parameters to describe the rate of
drug absorption into the tissue compartment and the ratio of observed tissue concentration to plasma concentration.
A, absorption compartment; C, clofazimine; CL, clearance; Cp, plasma concentration; H, isoniazid; K, kanamycin; ka,
rate of absorption; L, linezolid; M, moxifloxacin; P, peripheral compartment; PK, pharmacokinetic; PZA,
pyrazinamide; Q, intercompartmental clearance; R, rifampicin; V, volume.
https://doi.org/10.1371/journal.pmed.1002773.g003
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Rifampin. Overall, RIF distributed reasonably well into all lesion subtypes and compart-
ments, with penetration ratios ranging from 0.3 to 0.7. RIF concentrations were below the
MIC for less than 50% of the dosing interval in all tissue compartments in typical patients.
Only one patient had received multiple RIF doses, limiting the possibility to establish steady-
state residence time in lesions of interest.
Isoniazid. Concentrations of the other first-line drug, INH, were below the MIC for more
than 10 h of the dosing interval in the majority of lesion subtypes, except for fungal ball tissue.
Comparing tissue-penetration coefficients of INH between lesions, higher penetration was
observed in caseum from closed nodules and caseous fibrotic nodules, suggesting more rapid
and favorable penetration and affinity in this more difficult-to-treat caseous environment.
However, it has been found that INH has no detectable activity against nonreplicating bacilli
found in caseum [22], indicating that despite favorable penetration, adequate concentrations
are likely not reached in this compartment.
Fig 4. Visual predictive check of individual lesions and drugs. The visual predictive checks were simulated for 1,000 patients and are shown for all 7 drugs and 9 lesions.
The simulated concentration–time profiles are represented by a solid black line to represent the median (typical patient) at steady state, with the shaded light blue area
representing the 95% prediction interval of the 1,000 patients simulated. The red line represents the median of plasma–time concentrations after the first dose of each
respective drug. The dashed black line represents the respective MIC of each drug and is displayed below the drug name. The original observed data is overlaid on top of
the simulated bands as open circles to assess the ability of the model to capture both the median and distribution of the clinical data. Open red circles represent drug
concentrations of patients receiving their first doses, and black open circles represent observed data for patients who were at steady state at the time of resection. First dose
and steady state are overlaid in a single panel. A time-extended plasma visual predictive check is provided in S3 Fig. �PZA MIC of 12.5 mg/L is shown and is specific to an
acidic environment less than pH 5.8. MIC, minimum inhibitory concentration; CFZ, clofazimine; INH, isoniazid; KAN, kanamycin; LZD, linezolid; MFX, moxifloxacin;
NA, not available; PZA, pyrazinamide; RIF, rifampicin.
https://doi.org/10.1371/journal.pmed.1002773.g004
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Pyrazinamide. PZA is considered a treatment-shortening and sterilizing drug and per-
forms best in the acidic environments thought to be present in the phagolysomes of infected
macrophages and in the necrotic foci of closed nodules and cavities [23]. Differentiating lesion
subtypes based on their likely pH microenvironments, PZA should be most active in necrotic
nodules, macrophage rich lung, cavity wall, cavity caseum, closed nodule caseum, and small
cellular nodules. Considering lowered MIC in these lesion compartments, PZA concentrations
were above the “acidic” MIC for 9 h of the dosing interval in the caseum of closed nodules and
for at least 70% of the dosing interval in lung tissue, cavity wall, cavity caseum, cellular and
necrotic nodules, and fibrotic tissue.
Moxifloxacin. Second-line drugs MFX and CFZ (100 mg daily) had the highest lesion-
penetrating ratios with higher observed tissue than plasma concentrations. As a result, MFX
was above the MIC for the dosing interval in all lesion subtypes, including caseous lesions.
Clofazimine. CFZ had high-penetration ratios into cellular tissues, such as uninvolved
lung, cavity wall and small cellular nodules, and fibrotic lesions, translating into concentra-
tions above its MIC for the entire dosing interval. Penetration in tissues with little or no
Table 2. Plasma PK parameters.
Parameter RIF INH PZA MFX CFZ KAN LZD
Rate of absorption (h−1) 1.55 (0.0434) 0.738 (0.150) 0.554 (0.183) 1.55 (1.50) 0.100 (0.349) 1.65 (0.066) 2.13 (0.010)
Lag time (h) - 0.130 (0.230) - - - - -
Clearance (L/h) 5.72 (1.44) s: 9.41 (3.26)
i: 24.0 (9.41)
f: 38.1 (5.41)
2.05 (0.312) 8.93 (1.50) 16.3 (0.109) 4.61 (0.251) 3.77 (0.082)
Central volume (L) 52.3 (12.5) 48.9 (9.98) 30.0 (2.71) 147 (32.9) 280 (0.273) 30.6 (0.167) 145 (0.530)
Intercomp clearance - 6.43 (1.86) - - - - -
Peripheral volume (L) - 40.4 (14.3) - - - - -
Abbrievations: CFZ, clofazimine; f, fast; i, intermediate; INH, isoniazid; KAN, kanamycin; LZD, linezolid; MFX, moxifloxacin; NONMEM, NONlinear Mixed Effects
Modeling; PK, pharmacokinetic; PZA, pyrazinamide; RIF, rifampicin; s, slow.
�Standard error shown in parentheses describes the precision of the parameters generated by NONMEM. INH clearance was estimated for 3 subgroups representing s, i,
and f metabolizers.
https://doi.org/10.1371/journal.pmed.1002773.t002
Table 3. Estimated drug lesion ratios.
Drug Lung Cavity
wall
Small cellular
nodule
Caseum from
cavity
Closed nodule
caseum
Caseous fibrotic
nodule
Necrotic
nodule
Fibrotic
tissue
Fungal ball
RIF 0.694
(0.19)
0.614
(0.16)
0.348 (0.18) 0.449 (0.32) 0.443 (0.25) 0.733 (0.29) 0.569 (0.12) 0.539 (0.18) 0.447 (0.07)
INH 0.552
(1.20)
0.175
(0.80)
0.228 0.298 (0.42) 0. 824 (0.04) 0.516 (0.04) 0.376 (0.52) 0.267 (2.79) 3.04
(0.0004)
PZA 0.616
(0.17)
0.72 (0.02) 0.698 (0.04) 0.544 (0.13) 0.394 (0.32) 0.611 (0.032) 0.676 (0.09) 0.607 (0.04) 0.429
(0.001)
MFX 4.41 (2.29) 2.33 (0.77) 1.34 (1.46) 1.26 (0.37) 1.83 (2.24) 2.41 (0.99) 2.29 (1.16) 1.69 (1.46) 2.08 (0.01)
CFZ 12.4 (0.10) 11.3 (3.68) 11.47 (2.55) 1.34 (0.48) NA 14.3 (0.30) 7.32 (1.38) 22.03 (4.28) NA
KAN 0.404
(0.61)
0.468
(0.96)
0.422 (1.12) 0.468 (0.13) 0.176 (0.17) 0.503 0.667 (0.46) 0.404 (1.12) 0.918
LZD 0.609
(0.10)
0.497
(0.34)
0.531 (0.24) 0.651 (0.036) 0.673 (0.016) 0.177 (0.073) 0.609 (0.040) 0.487 (0.114) NA
Abbrievations: CFZ, clofazimine; INH, isoniazid; KAN, kanamycin; LZD, linezolid; MFX, moxifloxacin; NA, not available; PZA, pyrazinamide; RIF, rifampicin.
�Standard error shown in parentheses describes the precision of the parameters.
https://doi.org/10.1371/journal.pmed.1002773.t003
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cellularity, such as caseum from cavity, was low relative to other lesions. Thus, CFZ is expected
to reach cellular—but not caseous—lesion compartments at adequate concentrations, in line
with its reduced efficacy in mouse models that present large necrotic lesions [24]. In addition,
like INH, CFZ has no detectable activity against nonreplicating bacilli found in caseum [22].
Fig 5. PK profiles of individual drugs in at-risk patients relative to MIC. One thousand patients were simulated using the established model and the fifth percentile of
lower exposure shown with facets for individual drugs to compare drug penetration into respective lesions shown by different colors. The dashed line in the
concentration–time panel represents each drug’s respective MIC, and the bar graph below simplifies drug concentration above or below by black and white bars for each
lesion. Additionally, the total time drug concentration is above MIC at steady state over 24 h is printed next to each respective bar. Importantly, PZA’s MIC of 12.5 mg/L
is low-pH specific, which does not represent all the lesions’ pH environment. For the lesions with likely higher pH environments and assumed less PZA activity, gray
bars instead of black bars are used to indicate drug concentration above MIC. MIC, minimum inhibitory concentration; PK, pharmacokinetic; CFZ, clofazimine; INH,
isoniazid; KAN, kanamycin; LZD, linezolid; MFX, moxifloxacin; NA, not available; PZA, pyrazinamide; RIF, rifampicin.
https://doi.org/10.1371/journal.pmed.1002773.g005
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Kanamycin. A 1,000-mg dose of KAN had lower concentrations in tissues compared to
plasma and had a very low tissue-to-plasma ratio of 0.176 in caseum from closed nodules. The
highest estimated ratio of KAN was in necrotic nodules corresponding to the high Cmax/MIC
and a long time above MIC profile.
Linezolid. The typical profile of 300 mg LZD had best concentration levels and tissue-to-
plasma ratios in necrotic foci. Within most of the caseous lesions, LZD concentrations were
well maintained above MIC after reaching steady state.
At-risk patients show low target attainment in lesions
Next, the population PK model was implemented as a simulation tool to stratify patients at
risk of treatment failure. The population PK parameter estimates in our population corre-
sponded well to reported literature values (S2 Table) in general TB patient population; there-
fore, we assume that this population is similar in its PK profiles to the general population.
Considering that 95% of TB patients are successfully cured at the completion of standard treat-
ment for drug-susceptible TB, we investigated the lower fifth percentile of patient concentra-
tion–time profiles in plasma to account for the fraction of the population group that fails
treatment. This fifth percentile, was simulated from 1,000 repetitions at steady state for each
drug in lesion subtypes. The time above MIC is visualized for an at-risk patient in Fig 5. The
simulated at-risk population showed that first-line drug concentrations do not stay above the
respective MIC for the entire dosing interval. The horizontal timeline bars illustrate the period
during which a drug is above or below its MIC within a dosing interval in each of the 9 tissue
or lesion types. On average, RIF was below MIC values for hard-to-treat necrotic foci for less
than 50% of the dosing interval in at-risk patients. While INH reached adequate concentra-
tions in fungal ball tissue for the entire dosing interval and in caseous fibrotic nodule for half
of the dosing interval, in other lesions, INH was below its MIC more than 75% of its dosing
interval. In at-risk patients, PZA achieved concentrations above the MIC for 38%–55% of the
dosing interval in almost all lesion types, with caseum from cavity, closed nodule caseum, and
caseous fibrotic nodule showing the longest below-MIC periods, assuming an optimal acidic
MIC of 12.5 mg/L in all lesions.
Second-line CFZ achieved adequate exposure in cellular lesion compartments, consistent
with its higher intracellular uptake in macrophages and other immune cells. MFX performed
better than most drugs in all lesions, and while LZD performed well in all lesions in typical
patients, at-risk patients had less than 50% above-MIC concentrations—except for small cellu-
lar nodules. The ratio between peak concentration (Cmax) and MIC is generally considered the
PK/PD driver of aminoglycosides. In at-risk patient populations, the Cmax/MIC of KAN was
approximately 2-fold lower than in patients with standard exposure. Across drugs, closed nod-
ule caseum was the most problematic lesion compartment.
TB drugs do not reach their PK/PD target in all lesions
For most TB drugs, the exposure/potency index that drives efficacy is the ratio of the area
under the concentration curve to the MIC (AUC0–24/MIC). Published AUC0–24/MIC ratios—
associated with 90% maximal effective concentrations (EC90)—used in the present simulations
were 1,360 for RIF, 567 for INH, 56 for MFX, and 25 for LZD [15,16,25,26]. Aminoglycosides,
like KAN, generally show Cmax-dependent killing, and a Cmax/MIC value greater than 10 is
thought to result in 90% killing in the treatment of pneumonia [27]. In the absence of experi-
mental and clinical data for CFZ, 90% time above MIC was chosen as the PK/PD index.
Using simulations that represent the entire population, the results of the patient target
attainment simulation in lesions are shown in Fig 6. The simulation consisted of 1,000 patients
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Fig 6. Distribution of PK/PD target attainment per drug. Exposure of 1,000 simulated patients are represented as box plots in each lesion to visualize
the distributed PK/PD efficacy for individual drugs and lesions. Each panel represents an individual drug given at their standard dose until steady state
is reached. The dashed lines indicate published target attainment PK/PD ratios, for which black dashed lines indicate the critical exposure values able to
achieve�90% of maximal kill (EC90) values and gray dashed lines for drugs with published critical exposure values able to achieve�50% maximal kill
(EC50). The percentage of the 1,000 simulated patients are printed below each box plot. Lesions are colored by their vascularity. CC, caseum from cavity;
CN, closed nodule caseum; CW, cavity wall; EC90, 90% maximal effective concentrations; EC50, 50% maximal effective concentrations; FB, fungal ball;
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and showed improved outcomes for MFX and RIF, but INH and KAN performed poorly
across lesions, with only a small fraction of the patient population reaching target breakpoints
of efficacy. CFZ performed well across all lesion types except caseum from cavity.
Simulations can guide the selection of the best multidrug options for
patients with cavitary lesions
Overall, the plasma and lesion PK data collected in this study clearly highlight the impact of
interindividual PK variability and differential lesion penetration on PK/PD target attainment.
Importantly, the simulations uncover the potential for actual monotherapy in specific lesion
compartments where several drugs in the regimen do not reach adequate concentrations, cre-
ating windows of opportunity for the development of resistance in patients with low exposure
(Fig 7). The first-line regimen (RIF-INH-PZA) performed poorly in cavity and closed nodule
caseum, with only a maximum of 2 drugs with suitable drug levels in each lesion and sufficient
windows of monotherapy that could lead to resistance. Second-line drugs are included in S4
Fig. Collectively, the second-line drugs exhibited limited time above MIC in cavity caseum.
Using the PK/PD indices described in the previous section, we calculated the percentage
target attainment of each drug in each lesion type to identify regimens that would be effective
in specific lesions (Fig 8). Worst outcomes were predicted in cavity caseum and closed
FN, caseous fibrotic nodule; FT, fibrotic tissue; Lu, lung; NN, necrotic nodule; PK/PD, pharmacokinetic/pharmacodynamic; Pl, plasma; SN, small
cellular nodule.
https://doi.org/10.1371/journal.pmed.1002773.g006
Fig 7. Number of drugs above MIC by lesion type. Number of drugs above MIC over time plot of first-line drugs at steady state, collected as the fifth percentile (low-
exposure or at-risk patients) of 1,000 simulated patients over the 24-h dosing interval. Each square represents 1 h that a drug is above the MIC. The drugs are stacked for
each hour with different colors representing different drugs. Empty squares show no drug on board. MIC, minimum inhibitory concentration.
https://doi.org/10.1371/journal.pmed.1002773.g007
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Fig 8. Prediction of drug efficacy by lesion type. Using defined critical PK/PD exposure values, a population of 1,000 simulated patients were defined as
reaching efficacy or not from their PK simulations. The percentage of those reaching efficacy are shown as percentage box plots to compare the drugs that are
able to reach a higher ratio of efficacy in specific lesions. Black boxes represent the percentage population reaching EC90, and if available, gray boxes represent
the percentage population able to reach EC50. EC90, 90% maximal effective concentrations; EC50, 50% maximal effective concentrations; PK/PD,
pharmacokinetic/pharmacodynamics.
https://doi.org/10.1371/journal.pmed.1002773.g008
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nodules, with only RIF, MFX, and LZD reaching effective concentrations. First-line drug RIF
outperformed INH, which seldom impacted the population percentage reaching PK/PD tar-
gets. CFZ exhibited a contrasted profile, achieving high population percentages of target
attainment in cellular lesions while not contributing to efficacy in caseum. KAN did not meet
expectations and could benefit from dose optimization to ensure that lesion concentrations
are adequate to inhibit bacteria; however, KAN’s severe safety profile would limit such
optimization.
To further examine if the drugs could perform better at increased doses, dose-escalation
simulations of 600 mg and 800 mg MFX were performed but did not produce significant
changes in outcome (Fig 9A). High-RIF doses of 900 mg or 1,200 mg predicted 100% target
attainment in the simulated population. Simulated LZD doses of 600 mg twice daily and 1,200
mg daily showed improved efficacy outcomes almost 2-fold. Considering LZD toxicity is con-
centration driven, a 600-mg twice-daily dose would decrease risk of toxicity while still main-
taining AUC values similar to a 1,200-mg daily dose [28]. To account for the phenotypic drug
tolerance of Mycobacterium tuberculosis (Mtb) bacilli in nodule and cavity caseum [29], addi-
tional population PK/PD distributions were simulated using caseum-specific minimum bacte-
ricidal concentration MBC90 (CasMBC90) as the PD parameter to capture the drugs’ killing
potential in the caseous core of necrotic lesions (Fig 9B). None of the drugs were able to reach
full efficacy in this hard-to-treat lesion, and MFX was the only drug to show efficacy for 31%
of the simulated population. Additional results using MBC90 and casMBC90 in other lesions
are shown in S5 Fig.
Implementation of the established clinical model into interactive research
and clinical in silico tool
An online tool for the established model was developed to simulate different doses and sched-
ules for each of the 7 drugs in each specific lesion for any user-entered MIC. This interactive
tool can generate critical knowledge essential for drug treatment and regimen optimization in
a clinical trial setting by highlighting those patients at lower exposure that are at risk of treat-
ment failure and stratifying patients with and without cavity. The web app is hosted at http://
saviclab.org/tb-lesion/, with snapshots of 1 panel shown in Fig 10.
Discussion
We have described and modeled the penetration of 7 first- and second-line TB drugs in 9 dif-
ferent lesion types from clinically resected lung samples. The population PK and tissue distri-
bution model successfully captured the data and observed variance.
Overall, MFX, LZD, and RIF achieved the best coverage across lesion types relative to pub-
lished MIC values. Our MFX results are aligned with a recent study by Kempker and col-
leagues, who measured free-cavitary MFX concentrations between 1 and 6 μg/mL
approximately 2 h after drug administration [30]. In our simulations, to explore caseum-spe-
cific MBC (8 μg/mL for RIF and 2 μg/mL for MFX), RIF and MFX were remarkably the only 2
study drugs that could reach the concentrations required to kill 90% of nonreplicating Mtb
bacilli in caseum [22]. However, despite its good cidal activity in caseum, MFX does leave a
substantial population of persisters behind [22]; this could explain its lack of sterilizing activity.
Considering the disappointing results of the REMoxTB and RIFAQUIN trials, in which MFX
failed to shorten TB chemotherapy when substituted for either INH or ethambutol in the first-
line treatment of DS-TB [31,32], more studies into lesion-focused penetration and activity
could guide better decision-making for regimen and trial designs. In addition to MFX’s poor
sterilizing activity, Drusano and colleagues demonstrated an antagonism between RIF and
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MFX against nonreplicating bacilli in the hollow-fiber system [33]. Additionally, there is a sig-
nificant and clinically relevant drug–drug interaction between RIF and MFX, reducing MFX
Fig 9. Predicted contribution of drugs by lesion type. A. RIF, MFX, and LZD simulations were performed at higher doses to observe their impact in hard-to-treat
caseum from closed nodule. Their respective exposure distribution in 1,000 patients are shown in relation to their critical exposure value to reach EC90 (black lines), and
EC50 (gray bars) if available. B. The percentage PK/PD efficacy target reached by a 1,000 simulated patient PK profiles as defined by their drug exposure versus drug
MIC is shown in blue. Red boxes use CasMBC90 instead of MIC in the same set of simulated patients to compare that efficacy is both lesion and drug specific. EC90, 90%
maximal effective concentrations; LZD, linezolid; CasMBC90, caseum-specific minimum bactericidal concentration; MIC, minimum inhibitory concentration; MFX,
moxifloxacin; PK/PD, pharmacokinetic/pharmacodynamic; RIF, rifampicin.
https://doi.org/10.1371/journal.pmed.1002773.g009
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levels up to 40%, which would require dose adjustment, but is often not implemented due to
QT prolongation concerns [34]. In light of these observations, our results suggest that the clini-
cal utility of MFX may be maximized in a regimen that does not include rifamycin.
None of the drugs evaluated could reach their respective PK/PD targets in 100% of patients
with closed caseum nodules. The best outcome was seen with MFX at 93.2% and RIF at 65.2%.
CFZ reached adequate exposure in all cellular lesion types and lesion compartments, for which
PK/PD modeling indicates it contributes to regimen efficacy in a major way, except for cavity
caseum, for which CFZ failed to meet target attainment. This suggests that CFZ should always
be paired with TB drugs that can reach and kill bacterial populations residing in necrotic lesion
compartments. This could include RIF, MFX, or LZD, but care should be taken to ensure that
patients are not resistant to RIF if CFZ is used as a second-line drug. Considering these out-
comes, RIF-MFX-CFZ with or without LZD could potentially be the best treatment regimen
to treat the majority of patients with diverse lesions. A stratified treatment approach based on
the lesion profiles of patients could also be useful, for which patients with noncavitary TB and
limited pathology could be adequately treated with a short course regimen containing CFZ.
Our study offers further rationale for use of stratified medicine approaches in TB care for
which the right treatment as well as the right dose could be matched with the right patient to
ensure optimal treatment for all patients.
INH showed poor overall distribution and did not reach any PK/PD targets. In our cohort,
the majority of the patients were fast acetylators (11 out of 15), resulting in very low plasma
levels in a majority of the patients, which could skew the lesion results toward very low levels.
Considering these results, and based on our simulations, INH may not perform so poorly in
other regions of the world where distribution of acetylator status is more balanced. Adminis-
tration of high-INH dose could also help; for example, based on our simulations,
Fig 10. Interactive web application. A page of the web app is shown that displays 2 scenarios of a patient presenting with or without cavity. The user can investigate the
patient’s exposure distribution, dosing, and microbiology properties.
https://doi.org/10.1371/journal.pmed.1002773.g010
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administration of a daily 15-mg/kg dose in slow acetylators would result with some coverage
in caseum from cavity and closed nodule caseum.
KAN was another drug that performed poorly, and considering aminoglycoside cross-resis-
tance, serious side effects, and a less favorable view of injectable drugs for TB treatment due to
adherence problems, the use of KAN proves to be limited and of little value, as has recently
been confirmed in new WHO Rapid Communication: Key changes to treatment of multidrug-
and rifampicin-resistant tuberculosis (MDR/RR-TB) Guideline [35,36].
LZD showed good penetration into all lesions, confirming that LZD remains an excellent
drug choice for TB treatment, as recently observed in clinical trials or extensively drug-resis-
tant TB (XDR-TB) from an efficacy standpoint [37]. Use of LZD will remain limited by its tox-
icities, namely anemia and neuropathy, and an optimal risk/benefit ratio is yet to be
determined.
For all of our simulations, we have used general MIC targets as recommended by standard-
ized European Committee on Antimicrobial Susceptibility Testing/Clinical & Laboratory
Standards Institute (EUCAST/CLSI) methodology as well as literature [15,16]. The accuracy in
MIC measurements and any uncertainties around these values would carry over to the simula-
tions. More precise assessment of MIC, as recently recommended by Alland and colleagues,
would benefit accuracy and precision of our simulations [38]. For this reason, our interactive
tool allows the MIC of drugs to be adjusted by the user as new mycobacterial targets become
available.
Our patient population failed their initial TB treatment, and one of the potential reasons
could be overall low drug levels leading to suboptimal therapy. Low drug exposures could be a
consequence of nonadherence, reduced bioavailability, or increased clearance, all leading to
suboptimal drug levels compared to the general population. However, the plasma PK parame-
ter estimates from our models were within range of reported literature values. A recent
patient-pooled analysis showed that HIV seropositivity, low BMI, adherence, baseline burden,
and cavitation were all significant risk factors for treatment failure [39]. Both cavitation and
adherence would lead to reduced levels in the cavities despite satisfactory plasma levels.
Indeed, as shown in our study, drug levels in the cavities were very much reduced, which can
explain why cavitation is an important risk factor for poor treatment response and might con-
tribute to failing treatment in our cohort. Indeed, all patients had TB lesions so significant and
diverse that they required lung resection as treatment. Our study offers a pharmacological and
mechanistic explanation as to why cavitation indeed is such an important risk factor for TB
outcome.
Most of the TB drugs show large between-patient variability in plasma drug levels. To
explore the impact of PK variability, we have conducted population simulations to explore
how patients with very low plasma levels would perform in terms of lesion PK and PK/PD tar-
get attainment, providing further rationale for the likelihood of poor clinical response due to
suboptimal PK. First- and second-line drugs showed suboptimal concentrations in the lesions
of these patients, especially cavity caseum and closed nodule caseum, in agreement with the
poor prognostics associated with cavitary TB [39,40]. This also further suggests that a majority
of the TB drugs might not be used at their optimal dose.
Emergence of resistance is prevalent in cavities, and different resistant isolates have been
retrieved from different cavities of the same patient [41,42], pointing toward diverging resis-
tance evolution, depending on lesion-specific context (bacterial load, drug tolerance of local
populations [22], and fluctuating drug levels). Such lesion-specific acquired resistance is con-
sistent with suboptimal penetration of a subset of the TB drugs in nonvascularized cavity
caseum [7,9,43,44]. Our results, together with the recently demonstrated correlation between
sub-breakpoint MIC and relapse [38], point in the direction of spatial and temporal windows
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of de facto monotherapy for which only one drug is present at adequate (i.e., above the concen-
tration required to inhibit and/or kill local bacterial populations) concentrations during a sig-
nificant portion or all of the dosing interval.
The limitations of this study include the relatively small sample size and the fact that individ-
ual tissue samples could only be taken at one time point for each patient, which is the time of
the resection surgery. An additional limitation is that only one subject was at steady state for
RIF. While a nonlinear mixed effects approach is useful to evaluate sparse data sets, RIF esti-
mates did not capture the high caseum retention times observed in this specific patient [45],
indicating that steady-state exposure of RIF could have been underestimated in the current
model; however, any such interpretation is limited given this observation in only one patient.
Further, all subjects were under anesthesia at the time of lung resection, and this could have
affected drug distribution, metabolism, and elimination. The surgical procedure itself also led to
3 distinct types of lesions, namely vascular, avascular, and mixed lesion. For vascular and mixed
lesions, vascular tissue and/or spill-over blood from surgery could potentially affect the final
concentrations measured; however, this is likely to be negligible due to the pulmonary artery
being clamped during the procedure and the tissues briefly rinsed. Finally, patients underwent
lung resection due to failing their TB treatment, which may have selected for subjects that had
suboptimal lesion-specific drug exposure and introduced a bias in the type of lesions present.
In conclusion, our results suggest that target attainment is both lesion and drug specific.
This suggests that the current paradigm, according to which all patients receive the same regi-
men at the time of TB diagnosis, could be revisited. The results show that cavities and lesions
that contain caseum are the most difficult to treat, as their drug levels often do not reach ade-
quate levels over the course of treatment. It is therefore important to take special precautions
when treating patients with cavitation and monitor their outcomes closely. Stratifying patients
based on disease extent, lesion types, and individuals’ drug-susceptibility profiles, followed by
the rational selection of a tailored drug regimen, may lead to more adequate drug coverage of
bacterial subpopulations residing in TB lesions. To that end, we provide an interactive tool
that is able to estimate lesion-focused drug levels following any dose and schedule for these 7
drugs with the aim to support smarter design of regimens for clinical trial settings.
Supporting information
S1 Study protocol.
(PDF)
S1 Table. Number of observations for each lesion and drug.
(DOCX)
S2 Table. Plasma PK results compared to literature values. PK, pharmacokinetic
(DOCX)
S3 Table. Rate of drug moving from plasma to lesion (KPL) measured in (h−1). KPL, rate
parameter
(DOCX)
S1 Fig. Representative examples of the 9 tissue types analyzed in this study. Samples were
stained by HE and Mason’s trichrome for fibrosis. (A) HE staining of a lesion cluster including
(1) uninvolved lung, (2) small cellular granuloma, (3) necrotic nodule, and (4) closed necrotic
nodules with central caseum delineated by the white contour line, as indicated. (B) Mason’s
trichrome staining of (5) large caseous (necrotic) fibrotic nodules and (6) highlighting of the
fibrotic cuff in blue; (C) HE staining of a large cavity; most of the central caseum was lost upon
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sectioning. (7) Cavity wall delineates (8) remnants of caseum highlighted by the black contour
lines. (D) HE staining of a collapsed cavity with fragments of a (9) fungal ball marked by black
box and arrow. The hypha are shown in the inset above D. HE, hematoxylin–eosin.
(TIF)
S2 Fig. Role of rate and ration on plasma profile. Plasma profile is shown in black and exam-
ple of lesion profile shown in red. The KPL changes the profile on the time scale, while the
RPL scales the concentration dimension of the profile. KPL, rate parameter; RPL, ratio param-
eter.
(TIF)
S3 Fig. Visual predictive check of plasma over time to steady state. The visual predictive
checks were simulated for 1,000 patients and are shown for all 7 drugs in plasma. The simu-
lated concentration–time profiles are represented by a solid black line to represent the median
at steady state, with the shaded light blue area representing the 95% prediction interval of the
1,000 patients simulated. The red line represents the median of plasma–time concentrations
after the first dose of each respective drug. Open red circles represent drug concentrations of
patients receiving their first doses, and black open circles represent observed data for patients
who were at steady state at the time of resection. The dashed PK profiles serve to illustrate
drug exposure increasing after each dose until reaching steady state. �PZA MIC of 12.5 mg/L
is shown and is specific to an acidic environment less than pH 5.8. MIC, minimum inhibitory
concentration; PK, pharmacokinetic; PZA, pyrazinamide.
(TIF)
S4 Fig. Number of second-line drugs above MIC over time. Second-line drugs at steady state
collected as the fifth percentile (low-exposure or at-risk patients) of 1,000 simulated patients
over the 24-h dosing interval. Each square represents 1 h that a drug is above the MIC. The
drugs are stacked for each hour with different colors representing different drugs. MIC, mini-
mum inhibitory concentration.
(TIF)
S5 Fig. Percentage PK/PD target reached using minimum bactericidal concentration com-
pared to MIC. The percentage PK/PD efficacy target reached by a 1,000 simulated patient PK
profiles as defined by their drug exposure versus drug MIC is shown in blue and MBC shown
in yellow. Red boxes use CasMBC90 instead of MIC in the same set of simulated patients to
compare that efficacy is both lesion and drug specific. CasMBC90, caseum-specific minimum
bactericidal concentration; MIC, minimum inhibitory concentration; PK/PD, pharmacoki-
netic/pharmacodynamic.
(TIF)
S1 Data. Plasma concentration data for KAN, CFZ, and LZD. CFZ, clofazimine; KAN, kana-
mycin; LZD, linezolid.
(XLSX)
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